Breaking News Instant updates and real-time market news.

KITE

Acquired by GILD 9/17

$48.35

-2.21 (-4.37%)

, JUNO

Juno Therapeutics

$22.12

-0.89 (-3.87%)

07:26
11/29/16
11/29
07:26
11/29/16
07:26

Kite Pharma benefits from program delays at Juno, says Canaccord

Canaccord analyst John Newman believes Kite Pharma (KITE) will benefit from the program delays at Juno Therapeutics (JUNO). Two deaths in Juno's Phase 2 ROCKET trial may prompt safety questions for its drug to be used in refractory NHL, which raises the upside potential for Kite when its presents its data at the ASH conference. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.

KITE

Acquired by GILD 9/17

$48.35

-2.21 (-4.37%)

JUNO

Juno Therapeutics

$22.12

-0.89 (-3.87%)

  • 03

    Dec

  • 03

    Dec

KITE Acquired by GILD 9/17
$48.35

-2.21 (-4.37%)

10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/10/16
ADAM
10/10/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma BLA filing still expected by year end, says Canaccord
Canaccord analyst John Newman noted Kite Pharma released 12 month update on Zuma-1 Phase 1, which showed durable efficacy and is encouraging despite coming from a small patient group. The analyst saw the release as a continuation of positive trends and expects a BLA filing by the end of 2016. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.
JUNO Juno Therapeutics
$22.12

-0.89 (-3.87%)

11/25/16
SBSH
11/25/16
NO CHANGE
Target $34
SBSH
Buy
Citi still bullish on Juno's technology despite clinical hold
Citi analyst Robyn Karnauskas says she remains bullish on Juno Therapeutics' technology after the company voluntarily placed its JCAR015 ROCKET program on clinical hold following cerebral edema in two patients last week. Juno has the best data in both adult and pediatric acute lymphoblastic leukemia, Karnauskas told investors Wednesday in a research note. She expects the company's therapies will get used despite the safety risks and believes Juno will be able to find ways to slow the rate of cell proliferation and reduce toxicity. The analyst lowered her price target for Juno shares to $34 from $45 and kept a Buy rating on the name. Juno closed Wednesday down $7.32 to $22.56.
11/25/16
11/25/16
DOWNGRADE
Target $25

Hold
Juno Therapeutics downgraded to Hold at SunTrust
As previously reported, SunTrust analyst Peter Lawson downgraded Juno Therapeutics to Hold from Buy due to the reduced visibility and increased uncertainty that comes from the two additional deaths in the company's ROCKET trial of JCAR015. Citing the renewed issues with JCAR015, Lawson decreased his probability of success across the company's pipeline and lowered his price target for Juno shares to $25 from $48.
11/25/16
MAXM
11/25/16
NO CHANGE
Target $34
MAXM
Buy
Juno still has significant opportunity in 'no-option population,' says Maxim
Maxim analyst Jason McCarthy removed JCAR015 in adult ALL from his model for Juno Therapeutics after the company placed its ROCKET study on clinical hold for the second time following two additional patient deaths. Accordingly, the analyst lowered his price target on Juno shares to $34 from $50. However, McCarthy keeps a Buy rating on Juno shares, as he still believes CAR-T technology, and the company, has a "significant opportunity in the no-option population" and that regulators will agree when evaluating treatments intended to help patients that will otherwise die.
11/28/16
LEER
11/28/16
NO CHANGE
Target $34
LEER
Outperform
Juno Therapeutics price target lowered to $34 from $45 at Leerink
Leerink analyst Michael Schmidt lowered his price target for Juno Therapeutics to $34 from $45 following news that the pivotal ROCKET trial of its JCAR015 product candidate in adult acute lymphocytic leukemia has been placed on a clinical hold due to safety concerns. The analyst believes the future of the program is now increasingly uncertain as the company's management is trying to better understand the therapeutic window of JCAR015, raising the question of whether it moved into a pivotal trial too fast. Schmidt reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

BHGE

Baker Hughes

$34.63

-0.11 (-0.32%)

12:20
01/19/18
01/19
12:20
01/19/18
12:20
Options
Put buying in Baker Hughes ahead of earnings »

Put buying in Baker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.70

0.55 (3.63%)

12:19
01/19/18
01/19
12:19
01/19/18
12:19
Hot Stocks
Breaking Hot Stocks news story on Momenta 

Momenta trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:17
01/19/18
01/19
12:17
01/19/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASFI

Asta Funding

$7.35

0.05 (0.68%)

12:16
01/19/18
01/19
12:16
01/19/18
12:16
Hot Stocks
Asta Funding receives Nasdaq non-compliance letter »

Asta Funding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

12:16
01/19/18
01/19
12:16
01/19/18
12:16
Hot Stocks
NuCana to resume trading at 12:30 pm ET »

NuCana is scheduled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
01/19/18
01/19
12:16
01/19/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.15

-0.35 (-2.26%)

12:15
01/19/18
01/19
12:15
01/19/18
12:15
Hot Stocks
Breaking Hot Stocks news story on Momenta »

Momenta jumps 14%, halted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$14.27

0.18 (1.28%)

12:15
01/19/18
01/19
12:15
01/19/18
12:15
Options
MiMedx put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.15

-0.35 (-2.26%)

12:14
01/19/18
01/19
12:14
01/19/18
12:14
Periodicals
Breaking Periodicals news story on Momenta »

Momenta weighing options,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.15

-0.35 (-2.26%)

12:14
01/19/18
01/19
12:14
01/19/18
12:14
Hot Stocks
Breaking Hot Stocks news story on Momenta »

Momenta trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRG

NRG Energy

$26.50

-0.31 (-1.16%)

12:05
01/19/18
01/19
12:05
01/19/18
12:05
Options
NRG Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMNB

American National Bankshares

$39.10

-0.8 (-2.01%)

12:03
01/19/18
01/19
12:03
01/19/18
12:03
Hot Stocks
American National Bankshares announces 300,000 share repurchase program »

American National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBIB

Porter Bancorp

$13.76

0.06 (0.44%)

12:02
01/19/18
01/19
12:02
01/19/18
12:02
Hot Stocks
PBI Bank changes name to Limestone Bank »

In the first weeks of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

12:01
01/19/18
01/19
12:01
01/19/18
12:01
Hot Stocks
NuCana reports 'promising' clinical data on Acelarin »

NuCana announced interim…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

11:55
01/19/18
01/19
11:55
01/19/18
11:55
Hot Stocks
Breaking Hot Stocks news story on NuCana »

NuCana PLC (ADS) trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$46.51

-0.27 (-0.58%)

11:55
01/19/18
01/19
11:55
01/19/18
11:55
Options
Mylan put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 08

    Mar

BTC

Bitcoin

, BAC

Bank of America

$31.55

0.07 (0.22%)

11:52
01/19/18
01/19
11:52
01/19/18
11:52
Hot Stocks
The Intersection: Crypto and Wall Street This Week »

As bitcoin, ethereum and…

BTC

Bitcoin

BAC

Bank of America

$31.55

0.07 (0.22%)

MS

Morgan Stanley

$56.67

0.83 (1.49%)

GS

Goldman Sachs

$252.15

1.18 (0.47%)

V

Visa

$122.10

-1.015 (-0.82%)

AMD

AMD

$12.47

0.29 (2.38%)

NVDA

Nvidia

$224.44

-0.28 (-0.12%)

OSTK

Overstock.com

$71.25

-4.4 (-5.82%)

DPW

DPW Holdings

$2.30

-0.05 (-2.13%)

LBCC

Long Blockchain Corp.

$4.51

0.3 (7.13%)

KODK

Kodak

$10.05

-0.1 (-0.99%)

SSC

Seven Stars Cloud Group

$4.53

-0.1 (-2.16%)

RIOT

Riot Blockchain

$19.80

2.04 (11.49%)

LFIN

Longfin

$44.69

6.09 (15.78%)

TEUM

Pareteum

$2.37

0.01 (0.42%)

SRAX

Social Reality

$4.96

0.17 (3.55%)

GBTC

Bitcoin Investment Trust

$1,857.00

221 (13.51%)

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 30

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 15

    Feb

AOS

A.O. Smith

$66.32

0.41 (0.62%)

11:51
01/19/18
01/19
11:51
01/19/18
11:51
Hot Stocks
A.O. Smith announces 29% boost in dividend »

Directors of A. O. Smith…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Jan

TYME

Tyme Technologies

$6.15

-0.85 (-12.14%)

11:50
01/19/18
01/19
11:50
01/19/18
11:50
Hot Stocks
Tyme Technologies reports 'positive' efficacy data for SM-88 »

Tyme Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

AMOT

Allied Motion

$35.44

-0.06 (-0.17%)

11:48
01/19/18
01/19
11:48
01/19/18
11:48
Hot Stocks
Allied Motion acquires original equipment steering business from Maval »

Allied Motion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$220.33

2.83 (1.30%)

11:40
01/19/18
01/19
11:40
01/19/18
11:40
Technical Analysis
Technical Earnings Preview: Netflix near life highs before earnings news »

Shares are trading near…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

FXI

iShares China Large-Cap ETF

$51.64

0.565 (1.11%)

11:40
01/19/18
01/19
11:40
01/19/18
11:40
Options
Defensive option play in iShares China Fund as the rally continues »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$69.80

-0.56 (-0.80%)

, TTWO

Take-Two

$117.27

1.18 (1.02%)

11:33
01/19/18
01/19
11:33
01/19/18
11:33
Periodicals
NPD says 'Call of Duty: WWII' top selling game in U.S. in 2017, VentureBeat says »

NPD Group said that…

ATVI

Activision Blizzard

$69.80

-0.56 (-0.80%)

TTWO

Take-Two

$117.27

1.18 (1.02%)

EA

Electronic Arts

$115.28

2.14 (1.89%)

NTDOY

Nintendo

$52.69

1.155 (2.24%)

UBSFY

Ubisoft

$16.67

-0.31 (-1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 30

    Jan

  • 08

    Feb

  • 21

    Feb

  • 22

    Feb

  • 07

    Dec

BK

BNY Mellon

$55.89

0.535 (0.97%)

11:31
01/19/18
01/19
11:31
01/19/18
11:31
Hot Stocks
Street Fight: JPMorgan cuts BNY Mellon on tax reform moves, MS upgrades »

Shares of Bank of New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

ATVI

Activision Blizzard

$69.80

-0.56 (-0.80%)

, EA

Electronic Arts

$115.28

2.14 (1.89%)

11:30
01/19/18
01/19
11:30
01/19/18
11:30
Periodicals
Activision's 'Call of Duty: WWII' best selling game in Dec, VentureBeat says »

The NPD Group said that…

ATVI

Activision Blizzard

$69.80

-0.56 (-0.80%)

EA

Electronic Arts

$115.28

2.14 (1.89%)

NTDOY

Nintendo

$52.69

1.155 (2.24%)

TTWO

Take-Two

$117.27

1.18 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 30

    Jan

  • 08

    Feb

  • 21

    Feb

  • 22

    Feb

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.